Genetics of Heart & Vascular Disease

December 12-14, 2024
In-Person or Livestream | Hyatt Regency Grand Reserve - Puerto Rico, Rio Grande, Puerto Rico

Currently accepting registrations!
Credit Types: AMA PRA Category 1™ (15.5), Nursing (15.5), Price: $700-$800 | Register by 11/14 to save $100


Hyatt Regency Grand Reserve - Puerto Rico                                                                                                                                  
200 Coco Beach Blvd,
PR-955, Rio Grande,
00745, Puerto Rico

This program will be presented live in-person in Puerto Rico, USA and also is available via livestream Atlantic Standard timezone.

During this 3 day CME course, experts in the field of genetic cardiology and cardiovascular genetics detail the important role of genetics, genomics, and pharmacogenetics in the diagnosis, risk stratification, and treatment of monogenetic, oligogenetic, and polygenic diseases affecting the heart and the blood vessels.

Topics covered will include genetics and genomics 101, pharmacogenetics, polygenic risk scores, variant interpretation, the diagnostic, prognostic, & therapeutic implications of genetic testing for patients with congenital heart disease, long QT syndrome, Brugada syndrome, hypertrophic/dilated/arrhythmogenic cardiomyopathy, coronary heart disease, hyperlipidemias, heart failure, pulmonary hypertension, cardiac amyloid, and the aortopathies, the state of the molecular autopsy, and the state of gene therapy for CV diseases.

Unique Features:  Audience response system to enhance immediate feedback.  Easy access to faculty members.  One-on-one interaction.  Efforts will be made to introduce the clinical applications using new technology, however, there is no hands-on experience provided.  Self-assessment questions to gauge outcome.  Two “early bird” special workshops will be conducted to analyze your genetic test reports and to comment on the significance of the genetic test results and the implications for your patients.

Upon conclusion of this program, participants should be able to:

• Summarize the probabilistic nature of genetic testing
• Develop a strategy to manage the variant of uncertain significance (VUS) test result
• Identify the impact of genetic testing in the diagnosis, risk stratification, and treatment of patients with heritable cardiomyopathies, channelopathies, pulmonary hypertension, cardiac amyloidosis, and aortopathies 
• Determine the role of genetic testing in children and adults with congenital heart disease
• Define genetic markers of atherosclerosis and the role of genetic risk scores (GRS) in risk stratification of coronary heart disease
• Identify the genetic basis of heritable lipid disorders and implications for prevention and familial screening
• Define the role of pharmacogenetics in cardiovascular drug response, including the role of testing

Attendance at this Mayo Clinic course does not indicate nor guarantee competence or proficiency in the performance of any procedures which may be discussed or taught in this course.

This course is intended for both pediatric and adult cardiologists, internists, primary care providers, PAs,  nurse practitioners, nurses, pharmacists, pediatric and adult cardiology trainees, genetic counselors, and medical students with an interest in the management of patients with genetically mediated heart and vascular disease.  

Credit Types Offered
  • AMA PRA Category 1
  • Nursing

Price: $700-$800 | Register by 11/14 to save $100

Add to Cart

Cancellation, Refund and Other Conditions of Use

Additional Courses